Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 European Stocks Estimated To Be Trading Below Intrinsic Value By Up To 40.7%

In This Article:

As European markets show signs of recovery with the STOXX Europe 600 Index rising 3.93% over a week, investor sentiment is buoyed by the European Central Bank's recent rate cuts and delayed tariffs from the U.S., which have helped major indexes like Italy's FTSE MIB and Germany's DAX post significant gains. In this climate of cautious optimism, identifying stocks that are trading below their intrinsic value can present compelling opportunities for investors seeking to capitalize on potential market undervaluations.

Top 10 Undervalued Stocks Based On Cash Flows In Europe

Name

Current Price

Fair Value (Est)

Discount (Est)

Cenergy Holdings (ENXTBR:CENER)

€8.42

€16.42

48.7%

BFF Bank (BIT:BFF)

€7.50

€14.36

47.8%

Mips (OM:MIPS)

SEK352.60

SEK690.30

48.9%

LPP (WSE:LPP)

PLN15610.00

PLN30676.03

49.1%

Lindab International (OM:LIAB)

SEK186.80

SEK371.19

49.7%

Verbio (XTRA:VBK)

€9.24

€18.15

49.1%

TF Bank (OM:TFBANK)

SEK345.50

SEK668.99

48.4%

Etteplan Oyj (HLSE:ETTE)

€11.55

€23.09

50%

Komplett (OB:KOMPL)

NOK11.50

NOK22.64

49.2%

Fodelia Oyj (HLSE:FODELIA)

€7.14

€13.91

48.7%

Click here to see the full list of 176 stocks from our Undervalued European Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Asmodee Group

Overview: Asmodee Group AB (publ) is involved in the publishing and distribution of tabletop games, with a market cap of SEK21.27 billion.

Operations: The company generates revenue of €1.30 billion from its Games & Toys segment.

Estimated Discount To Fair Value: 36.7%

Asmodee Group is trading at 36.7% below its estimated fair value, with a stock price expected to rise by 25.5%, according to analysts. The company recently completed €640 million in fixed-income offerings, enhancing its financial flexibility. Although forecasted revenue growth of 4.8% annually surpasses the Swedish market average, its return on equity remains low at an anticipated 8.4%. Asmodee's earnings are projected to grow significantly at 68.61% per year, supporting its undervaluation based on cash flows.

OM:ASMDEE B Discounted Cash Flow as at Apr 2025
OM:ASMDEE B Discounted Cash Flow as at Apr 2025

Xvivo Perfusion

Overview: Xvivo Perfusion AB (publ) is a medical technology company based in Sweden that develops and markets machines and perfusion solutions to assess and maintain organs for transplantation, with a market cap of SEK8.80 billion.

Operations: Xvivo Perfusion AB (publ) generates revenue from three main segments: Services (SEK87.76 million), Thoracic (SEK555.24 million), and Abdominal (SEK179.42 million).